Grants per year
Personal profile
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Education/Academic qualification
Medicine, MD, Beijing Medical University
… → 1995
Epigenetics and Chromatin Biology, PhD, Syracuse U Main Camp
… → 1994
Fingerprint
Dive into the research topics where Janice Lu is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
Grants
- 1 Active
-
Prot #D9722C00001: A Randomised, Open-Label, Phase III Study of Saruparib (AZD5305) Plus Camizestrant Compared with Physician’s Choice CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant for the First-Line Treatment of Patients with BRCA1, BRCA2,
Lu, J. (PD/PI)
AstraZeneca Pharmaceuticals LP
2/19/25 → 2/19/28
Project: Research project
-
Current and future immunotherapy for breast cancer
Heater, N. K., Warrior, S. & Lu, J., Dec 2024, In: Journal of Hematology and Oncology. 17, 1, 131.Research output: Contribution to journal › Review article › peer-review
Open Access6 Scopus citations -
Elacestrant in ER+, HER2-Metastatic Breast Cancer with ESR1-Mutated Tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy plus CDK4/6 Inhibitor and in Clinical Subgroups
Bardia, A., Cortés, J., Bidard, F. C., Neven, P., Garcia-Sáenz, J., Aftimos, P., O'Shaughnessy, J., Lu, J., Tonini, G., Scartoni, S., Paoli, A., Binaschi, M., Wasserman, T. & Kaklamani, V., Oct 1 2024, In: Clinical Cancer Research. 30, 19, p. 4299-4309 11 p.Research output: Contribution to journal › Article › peer-review
Open Access17 Scopus citations -
Tolerance and activity of oxaliplatin with protracted topotecan infusion in patients with previously treated ovarian cancer. A phase I study
Hochster, H., Chen, T. T., Lu, J. M., Hills, D., Sorich, J., Escalon, J., Ivy, P., Liebes, L. & Muggia, F., Mar 2008, In: Gynecologic oncology. 108, 3, p. 500-504 5 p.Research output: Contribution to journal › Article › peer-review
Open Access7 Scopus citations -
Emerging treatments for ovarian cancer
Muggia, F. & Lu, M. J., May 2003, In: Expert Opinion on Emerging Drugs. 8, 1, p. 203-216 14 p.Research output: Contribution to journal › Review article › peer-review
7 Scopus citations -
Intraperitoneal therapy as consolidation for patients with ovarian cancer and negative reassessment after platinum-based chemotherapy
Lu, M. J., Sorich, J., Hazarika, M., Kim, M., Del Priore, G., Jacobs, A. J., Chiang, C., Liu, P. C., Fusco, E., Curtin, J. P. & Muggia, F. M., Aug 2003, In: Hematology/Oncology Clinics of North America. 17, 4, p. 969-975 7 p.Research output: Contribution to journal › Review article › peer-review
5 Scopus citations